US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.77

+0.06820.28%

Post-market: 24.820.0518+0.21%19:30 EDT

Volume:23.89K

Turnover:594.14K

Market Cap:55.60M

PE:- -

High:25.07

Open:25.01

Low:24.73

Close:24.70

52wk High:27.02

52wk Low:15.63

Shares:2.24M

Float Shares:2.24M

Volume Ratio:0.61

T/O Rate:1.06%

Dividend:1.70

Dividend Rate:6.88%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)

NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review

Analysts Are Bullish on Top Healthcare Stocks: Relmada Therapeutics (RLMD), Delcath Systems (DCTH)

FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA

FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval

NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review

THOMSON REUTERS

NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval

THOMSON REUTERS

NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting

THOMSON REUTERS

FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

THOMSON REUTERS

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Wingara Ag sets AGM to approve capital raising tools and board re-elections

Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Relmada Therapeutics Q2 EPS USD -0.11

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

The Race to Come up with the Next Big Sleep Drug

Compass Pathways is Maintained at Overweight by Morgan Stanley

Compass Pathways price target raised to $22 from $17 at B. Riley

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/PSIL/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.7682,"timestamp":1789156800000,"preClose":24.7,"halted":0,"volume":23894,"hourTrading":{"tag":"盘后","latestPrice":24.82,"preClose":24.7682,"latestTime":"19:30 EDT","volume":41,"amount":1012.1888,"timestamp":1789169404986,"change":0.0518,"changeRate":0.002091,"amplitude":0},"delay":0,"changeRate":0.002761133603238904,"floatShares":2244976,"shares":2244976,"eps":0,"marketStatus":"Market Closed","change":0.0682,"latestTime":"09-11 16:00:00 EDT","open":25.01,"high":25.065,"low":24.73,"amount":594144.14202,"amplitude":0.013563,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":24.7,"sharesOutstanding":1184976,"nav":24.85,"aum":57650992.8,"dividendRate":0.06883,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":24.9423,"preClose":24.7,"latestTime":"09:15 EDT","volume":15,"amount":370.79841,"timestamp":1789132538199,"change":0.2423,"changeRate":0.00981,"amplitude":0.022603},"postHourTrading":{"tag":"盘后","latestPrice":24.82,"preClose":24.7682,"latestTime":"19:30 EDT","volume":41,"amount":1012.1888,"timestamp":1789169404986,"change":0.0518,"changeRate":0.002091,"amplitude":0},"volumeRatio":0.6079836362295901,"impliedVol":0.5428,"impliedVolPercentile":0.9004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2244976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6079836362295901,"shares":2244976,"dividePrice":1.7048,"high":25.065,"amplitude":0.013563,"preClose":24.7,"low":24.73,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.7682,"eps":0,"divideRate":0.06883,"volume":23894,"delay":0,"ttmEps":0,"open":25.01,"prevYearClose":17.17,"prevWeekClose":24.86,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.59,"twentyDayClose":25.2456,"sixtyDayClose":19.5761},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657626537","title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626537","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626537?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":"Conference Call 8:30 a.m. ET, Monday, August 10, 2026MIAMI, Aug.  07, 2026  (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341373/0/en/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL",".IXIC","QQQE","SQQQ","BK4181","BK4585","QQQM","BK4218","PSQ","QLD","NRXP","TQQQ","QID","QQQ","QQQY","QYLG","TECS","QQQJ","NVIW.SI","GPIQ","QDTE","NDX","LABU","BK4007","IYW","MNQmain","ONEQ","BK4588","FTEC","HST","JEPQ","NQmain","QQQA","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640437","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657640437?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:30","pubTimestamp":1786120219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nrx-pharmaceuticals-nrxp-novo-nordisk-nvo-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nrx-pharmaceuticals-nrxp-novo-nordisk-nvo-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0289739699.SGD","THNR","LU0225771236.USD","NVO","IE00BKVL7J92.USD","LU1894683264.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0225284248.USD","SG9999013999.USD","OZEM","BK4592","LU0321505868.SGD","LU0122379950.USD","LU0154236417.USD","LU1093756325.SGD","LU2596442595.SGD","LU1057294990.SGD","NVOH","LU1093756168.USD","BK4581","BK4007","BK4550","LU0868494617.USD","SG9999003800.SGD","SG9999001176.USD","BK4532","SGXZ57979304.SGD","PPH","LU1066051498.USD","LU1023059063.AUD","NVOX","PFE","BK4599","SG9999002232.USD","BK4568","BK4588","LU0985481810.HKD","IE00BLSP4452.SGD","IE00B3T34201.USD","LU1894683348.USD","PSIL","SG9999002224.SGD","LU0058720904.USD","LU0306807586.USD","NRXP","IE00B19Z3B42.SGD","IE0002270589.USD","LU0234572021.USD","LU0170899867.USD","LU0306806265.USD","IE00BLSP4239.USD","LU0456855351.SGD","IE00BZ1G4Q59.USD","LU1883839398.USD","LU0321505439.SGD","BK4534","SG9999011175.SGD","BK4533","SG9999001176.SGD","LU1066053197.SGD","BK4585","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657980640","title":"NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657980640","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657980640?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:24","pubTimestamp":1786119840,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals shares rose after the Food and Drug Administration completed its abbreviated new drug application review of the company's ketamine product.The stock climbed 21% to $3.73 on Friday. Shares are up 42% this year.The first-cycle review evaluated NRx's preservative-free ketamine and found no major deficiencies related to the product, ingredients or labeling, the drug company said Friday.The FDA did flag a remaining question related to the container closure of the medication vial. The issue is packaging-related and doesn't relate to the ketamine drug product itself, NRx said.The company is providing an attestation to the FDA related to the packaging issue.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NRXP","BK4007","PSIL","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657664119","title":"Analysts Are Bullish on Top Healthcare Stocks: Relmada Therapeutics (RLMD), Delcath Systems (DCTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657664119","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657664119?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:00","pubTimestamp":1786111242,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Relmada Therapeutics (RLMD), Delcath Systems (DCTH) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-relmada-therapeutics-rlmd-delcath-systems-dcth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-relmada-therapeutics-rlmd-delcath-systems-dcth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4082","RLMD","DCTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610077","title":"FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610077","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610077?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:21","pubTimestamp":1786101688,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals (NRXP) announced that the FDA has completed first-cycle review of the company’s ANDA for its preservative-free ketamine, with n...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-completes-review-of-nrx-pharmaceuticals-preservative-free-ketamine-anda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-completes-review-of-nrx-pharmaceuticals-preservative-free-ketamine-anda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","PSIL","BK4585","BK4588","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061084","title":"FDA Flags Packaging Certification as Sole Major Deficiency for NRx Preservative-Free Ketamine ANDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061084","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657061084?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:01","pubTimestamp":1786100507,"startTime":"0","endTime":"0","summary":"FDA flags packaging certification as sole major deficiency for NRx preservative-free ketamine ANDA approvalFDA completed first-cycle review of NRX Pharmaceuticals’ preservative-free ketamine ANDA with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL6YBV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757432546.USD","IE00BN0W2V16.EUR","PSIL","BCDF","LU0282719219.EUR","LU0640478920.SGD","LU0314104364.USD","LU2210150020.SGD","BK4585","SG9999014021.USD","SG9999014013.SGD","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP","NRXP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU1815337578.USD","BK5026","LU0757432629.USD","IE00BGHQF748.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","LU1815337495.USD","LU2210149790.SGD","BK4007","FAN.UK","BK4588","NDAQ","LU0728928796.USD","LU2095319765.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617099","title":"NRX Pharmaceuticals - FDA Finds no Major Deficiencies in Ketamine Anda First-Cycle Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617099?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617087","title":"NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617087?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657170556","title":"NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2657170556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657170556?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161707","title":"FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657161707?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699541","title":"These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699541?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:15","pubTimestamp":1786079700,"startTime":"0","endTime":"0","summary":"Biotech stocks have recaptured investors' attention this year amid a wave of drug innovation, which is spurring merger-and-acquisition activity in the biopharma industry and a fresh round of initial p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","LU2125154778.USD","IE000M9KFDE8.USD","LU0122379950.USD","NVS","LU1934455194.USD","LU1941712348.USD","PPH","IE00B1BXHZ80.USD","LU0061475181.USD","PAWZ","GDOC","LU1974910355.USD","LU0306807586.USD","SG9999014575.USD","PSIL","MRK","VHT","IE00BJJMRZ35.SGD","FHLC","RXL","XBI","XLV","LU2596442595.SGD","BMED","PBLS","HRTS","TRUH","LU0320765489.SGD","MEDX","LU0456855351.SGD","JDOC","LU1929549753.HKD","LU2461242641.AUD","LU1430594728.SGD","IHE","BMY","LU0965508806.USD","FTXH","BK4578","IXJ","BBC","LU2491050154.USD","SG9999001440.SGD","LU1261432733.SGD","LU0980610538.SGD","IYH","LU1023059063.AUD","LU1061106388.HKD","LU1037948541.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657529664","title":"Wingara Ag sets AGM to approve capital raising tools and board re-elections","url":"https://stock-news.laohu8.com/highlight/detail?id=2657529664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657529664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:29","pubTimestamp":1786058949,"startTime":"0","endTime":"0","summary":"Wingara Ag Ltd. ( ($AU:WNR) ) has issued an update. Wingara Ag Ltd has called its Annual General Meeting for 7 September 2026 in Melbourne, where s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/wingara-ag-sets-agm-to-approve-capital-raising-tools-and-board-re-elections?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/wingara-ag-sets-agm-to-approve-capital-raising-tools-and-board-re-elections?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","PSIL","BK4229","AGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666177","title":"Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666177","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666177?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:49","pubTimestamp":1786052975,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryRelmada Therapeutics IncRLMD.OQreported a quarterly adjusted loss of 11 cents per share for the quarter ended J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433IS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657931666","title":"Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657931666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657931666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:41","pubTimestamp":1786052519,"startTime":"0","endTime":"0","summary":"Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancerRelmada outlined NDV-01 as its lead program, a sustained-release intravesical gemcitabine/doce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1WTVbn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","RLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BK4007","LU2065171402.SGD","NBIX","BK4563","LU0154245673.USD","LU0109394709.USD","LU0320765992.SGD","LU2065169927.USD","IBRN","LU0889565916.HKD","IMRX","PSIL","LU2065171311.SGD","GHRS","IE00BFTCPJ56.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","BK4539","IE00B4R5TH58.HKD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","PRAX","LU0823416689.USD","LU2065170008.USD","IE0002141913.USD","LU0154245756.USD","IE00BJT1NW94.SGD","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657579136","title":"Relmada Therapeutics Q2 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2657579136","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657579136?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:06","pubTimestamp":1786046764,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Q2 EPS USD -0.11Aug 06 (Reuters) - Relmada Therapeutics Q2 net income USD -12.9 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX88ZKJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657184","title":"Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657184?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP. manufacturing of clinical trial material underway. Initiation of the. Phase 3 RESCUE registrational program upon IND clearance.-- Sepranolone IND filing expected by year-end 2026 and initiation of Phase. 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.-- Strengthened the leadership team with appointment of Bipin Dalmia as. -- Added to the Russell 2000 and Russell 3000 Indexes effective June. -- Cash balance of $217.7 million as of June 30, 2026, expected to fund. operations through 2029, including completion of the NDV-01 Phase 3","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLO","LU2413666699.HKD","LU2746668974.SGD","IE00B1BXHZ80.USD","LU2041044095.USD","CMC","BK4588","R","LU2229751404.USD","LU2237443978.SGD","IE00BHPRN162.USD","BK4585","LU2237443465.HKD","LU2237443895.HKD","LU2237443549.SGD","BK4139","IND","LU1721428933.USD","LU1721429741.USD","PWS","LU2092937221.SGD","BK4567","LU2089279066.USD","LU0149725797.USD","BK4232","IE00BFXG1179.USD","LU0882574139.USD","LU0347712357.USD","BK4121","BK4539","IE00BN0W2V16.EUR","LU2413666426.HKD","EES","IE00BN0W2W23.USD","RLMD","BK4006","BK4505","LU0170899867.USD","A","LU2237443622.USD","IE00BN0W2T93.GBP","IE00BZ1G4Q59.USD","PSIL","LU1543694498.USD","LU0971096721.USD","LU1721429402.USD","LU2746668461.USD","LENZ","IE00BKVL7J92.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651052","title":"The Race to Come up with the Next Big Sleep Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651052?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:30","pubTimestamp":1786041000,"startTime":"0","endTime":"0","summary":"Narcolepsy isn't easy to treat. Existing drugs manage patients' symptoms -- notably excessive daytime sleepiness and difficulty sleeping at night -- rather than the cause. Yet a new type of drug is em","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0471298777.SGD","LU0354030438.USD","IXJ","LU0158827781.USD","LU1814569148.SGD","LU2089284900.SGD","LU2271345857.HKD","ELIL","LU1267930730.SGD","LLYZ","PSCH","LU0203202063.USD","LU0198837287.USD","IE00B1BXHZ80.USD","IE00BK4W5M84.HKD","IE00BKPKM429.USD","BK4599","IYH","LU1366192091.USD","LU2106854487.HKD","IE00BJJMRX11.SGD","LU2237443978.SGD","LU2168564149.EUR","LU0943347566.SGD","LU2211815571.USD","LU0456855351.SGD","MEDX","LU0353189680.USD","LU1551013342.USD","SG9999013999.USD","LU1974910355.USD","LU1127390331.HKD","LU1323610961.USD","LU1988902786.USD","LU1061106388.HKD","SG9999014906.USD","LU1023059063.AUD","LU2602419157.SGD","IE0004445015.USD","LU1280957306.USD","LU1983299246.USD","LU1093756325.SGD","LU2023251221.USD","LU0345770308.USD","TRUH","LU0417517546.SGD","LU0234572021.USD","BK4007","LU1804176565.USD","LU2552382132.HKD","LU2756315318.SGD","LU0882574055.USD","LU2168563687.JPY","LU2237443895.HKD","LU2552382215.SGD","LU2264538146.SGD","LU2461242641.AUD","SGXZ57979304.SGD","LU2108987350.USD","IE0001KFT4U8.USD","LU2360106947.USD","SG9999018857.SGD","IE0009355771.USD","LU0345770993.USD","LU2468319806.SGD","SG9999017495.SGD","LU0823416689.USD","LLY","LU0238689110.USD","LU0079474960.USD","LU1868837136.USD","LU2750360997.AUD","LU0689472784.USD","LU1868837300.USD","SGXZ99366536.SGD","IE00B1XK9C88.USD","LU1629891620.HKD","LU2491050071.SGD","IE0005OL40V9.USD","LU0097036916.USD","LU0094547139.USD","LU2168564065.EUR","GB00BDT5M118.USD","IE00B7KXQ091.USD","LU2089984988.USD","LU2471134523.USD","SG9999015978.USD","LU2456880835.USD","LU1035775433.USD","SG9999001176.USD","ILDR","IE00BFSS7M15.SGD","LU0158827948.USD","FBT","RXL","LU2361044949.HKD","LU0006306889.USD","LU2112291526.USD","GDOC","LU1145028129.USD","LU2361045086.USD","LU0133085943.USD","WDNA","LU0256863902.USD","LU2168564495.EUR","BK4581","ELIS","LU0174119429.USD","BK4585","IE00BKDWB100.SGD","LU2491050154.USD","IE00B2B36J28.USD","LU0882574139.USD","LU0432979614.USD","LU0640476718.USD","LU1093756168.USD","LU1868836757.USD","LU2237443549.SGD","LU2237438978.USD","IE00BFSS8Q28.SGD","IE0004445239.USD","IE00BJLML261.HKD","LU2471134796.USD","CANC","LU1064131342.USD","LU1979441026.SGD","LU1868836591.USD","LU2237443622.USD","LU0385154629.USD","LU0820561909.HKD","LU0823434740.USD","LU1917777945.USD","LU2746668461.USD","MEDI","LU2237443382.USD","BK4533","LU2462591350.SGD","LU2236285917.USD","XLV","LU0109391861.USD","LU2417539215.USD","LU2896262040.SGD","LU2746668974.SGD","IE00BJJMRZ35.SGD","LLYX","LU2471134879.HKD","LU0106261372.USD","LU0225283273.USD","SG9999015945.SGD","FHLC","LU1291159041.SGD","LU2361044865.SGD","LU1712237335.SGD","AGNG","IE00B4R5TH58.HKD","LU0210536198.USD","LU2087625088.SGD","SGXZ31699556.SGD","BK4588","FTXH","LU0266013472.USD","SG9999018865.SGD","TMED","IE00BJJMRY28.SGD","LU1989771016.USD","LU2023250504.SGD","IBRN","LU0354030511.USD","IE00BJT1NW94.SGD","LU2028103732.USD","LU2237443465.HKD","LU0683600562.USD","VHT","BK4516","LU0820561818.USD","LU2023250330.USD","SG9999014898.SGD","LU0786609619.USD","LU0708995401.HKD","LU2089283258.USD","SG9999015986.USD","SGXZ51526630.SGD","BK4534","LU1548497426.USD","PPH","LU2265009873.SGD","SG9999014880.SGD","LU0964807845.USD","LU0353189763.USD","LU2324357040.USD","IHE","OZEM","LU0058720904.USD","SGXZ81514606.USD","LU2471134952.CNY","TAK","LU1623119135.USD","LU2750360641.GBP","LU0061475181.USD","IE00B775H168.HKD","LU0109394709.USD","PJP","PSIL","LU0672654240.SGD","LU2213496289.HKD","THNR","LU1868836914.USD","LU0256863811.USD","IE00BFTCPJ56.SGD","LU0096364046.USD","SG9999015952.SGD","LU0203201768.USD","LU1069344957.HKD","LU0889565916.HKD","LU1551013425.SGD","IE00BN29S564.USD","IE00BK4W5L77.USD","JDOC","LU0316494557.USD","LU0320765059.SGD","LU0320765992.SGD","LU0122379950.USD","LU1232071149.USD","LU0114720955.EUR","BK4139","LU2168564222.USD","LU2462157665.USD","LU1720051017.SGD","LU0289739699.SGD","LU1720051108.HKD","SG9999014914.USD","LU0466842654.USD","LU2357305700.SGD","LU1057294990.SGD","ALKS","LU0471298694.HKD","LU0823434583.USD","HRTS","LLII","LU2111349929.HKD","LU2491049909.HKD","IE00B4JS1V06.HKD","LU0323591593.USD","CURE","LU2063271972.USD","LU0787776722.HKD","LU2552382058.USD","MHIP","SG9999001176.SGD","IE0002141913.USD","LU2756315664.SGD","IE00BWXC8680.SGD","LU0820562030.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651829","title":"Compass Pathways is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651829","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651829?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:55","pubTimestamp":1786038900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637864","title":"Compass Pathways price target raised to $22 from $17 at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637864?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:38","pubTimestamp":1786023496,"startTime":"0","endTime":"0","summary":"B. Riley analyst Madison El-Saadi raised the firm’s price target on Compass Pathways (CMPS) to $22 from $17 and keeps a Buy rating on the shares po...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-raised-to-22-from-17-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-raised-to-22-from-17-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}